OpportunityAnalyzer:高雪氏症 - 機會分析與預測
OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and Forecast to 2024
|出版日期||內容資訊||英文 244 Pages
|OpportunityAnalyzer:高雪氏症 - 機會分析與預測 OpportunityAnalyzer: Gaucher Disease - Opportunity Analysis and Forecast to 2024|
|出版日期: 2015年12月01日||內容資訊: 英文 244 Pages||
主要7個國家(美國、法國、德國、義大利、西班牙、英國、以色列) 的高雪氏症的治療藥市場，從2014年的8億7,500萬美元，預計2024年擴大到11億6,000萬美元規模，以2.9％的年複合成長率 (CAGR) 增加。
GlobalData estimated the 2014 sales for the Gaucher Disease (GD) market at approximately $875m across the 7MM (US, France, Germany, Italy, Spain, UK, and Israel). The US market contributed the majority of these sales, generating an estimated $482m. By the end of the forecast period in 2024, GD sales are expected to increase to $1.16 billion at a Compound Annual Growth Rate (CAGR) of 2.9%. The majority of these sales will continue to come from the US, which will represent approximately 56.2% of the GD market in the 7MM in 2024. GlobalData forecasts an increase in the number of diagnosed prevalent cases of GD, and therefore, an increase in the treated GD population. Improved diagnosis will be driven by increasing physician education and awareness of GD and its signs and symptoms. Despite the anticipated increase in the number of diagnosed prevalent cases of GD over the forecast period, it is expected that a large portion of the GD population will remain undiagnosed. This is due to continued late diagnosis and misdiagnosis of GD as a result of the heterogeneous manifestations of the disease. The sparsely populated GD pipeline, with no drugs in late-stage development, will further hinder the growth of the GD market.
The report will enable you to -